SuperworthNextCure price to sales ratio NXTC
Market value divided by revenue over the last twelve months, since 2020.
- Today, Oct 23, 2026
- n/m
- not a meaningful number
- Last meaningful
- 8.6×
- Jul 2021
- Peer median
- 0.4×
NextCure's price to sales ratio is not a meaningful number today: revenue for one or more of the four quarters through 2026-06-30 is missing, so twelve months can't be added up.
It was last meaningful in Jul 2021, at 8.6×.
Price to sales ratio over time
Year by year
| Year | End of year | Low | High |
|---|---|---|---|
| 2021 | 8.6× | 8.6× | 15.6× |
| 2020 | 12.3× | 8.8× | 174× |
Against its peers
Companies in Drug Manufacturers - General nearest NextCure's size, closest first, today.
| Company | Price to sales ratio |
|---|---|
| NXTCNextCure | n/m |
| ATNMActinium Pharmaceuticals | n/m |
| SPROSpero Therapeutics | 1.4× |
| LFVNLifevantage | 0.4× |
| NATRNatures Sunshine Products | 0.4× |
| Peer median | 0.4× |
What the price to sales ratio tells you
Market value divided by revenue over the last twelve months. Useful for companies with little or no profit yet, since sales are harder to make negative than earnings.
Ignores margins entirely. A software company at 10× sales with 30% margins can be cheaper than a grocer at 1× sales with 2% margins.
More on NextCure
Valuation data, not investment advice. Prices as of . Reported figures come from the company's filings with the SEC.